Table 2.
Modification | Gene | Gene function | Clinical effect | Tumor | Ref. |
Hypermethylation (Inactivation) | |||||
RASSF1 | Induces cell cycle arrest | Correlated with malignancy, levels highest in metastases | PNET > GI-NET | [32-34] | |
INK4a/p16 | Induces cell cycle arrest and apoptosis | Decreased 5-yr survival, liver metastases | PNET, gastrinoma | [38,39] | |
MGMT | DNA repair | Improved response to temozolomide | PNET | [32] | |
TIMP-3 | Inhibits metalloproteinases | Correlated with metastases | PNET | [44] | |
UCHL-1 | Post-translational modifier, de-ubiquitinates proteins marked for lysosomal degradation | Correlated with metastases | GEP-NET | [45-47] | |
IGF2 | Chromatin packaging | Specific for insulinomas, increased stage | Insulinoma | [51] | |
MLH1 | DNA repair | Correlated with malignancy | PNET, insulinoma | [52] | |
Global hypomethylation | |||||
LINE-1 | Repeating long interspersed nucleotide elements | Correlated with malignancy and lymph node metastases | Ileal NET > GEP-NET | [53-55] | |
Alu | Repeating long interspersed nucleotide elements | Correlated with malignancy | GEP-NET | [54] |
GEP-NETs: Gastroenteropancreatic neuroendocrine tumors; PNETs: Pancreatic tumors; GI-NETs: Gastrointestinal tumors.